tirzepatide vs semaglutide weight loss study vs. for tirzepatide vs semaglutide weight loss

()

Schernthaner and Schernthaner, 2020), metformin is associated with gastrointestinal side effects in around 20% of patients, including nausea, vomiting, diarrhea, bloating, and occasionally lactic acidosis and vitamin B12 malabsorption

Whilst there is a range of possibilities that would require large-scale investigation, the authors also hypothesize that these discrepancies arise as women are less likely to have insulin abnormalities and are less susceptible to its detrimental effects

The practical result is that a large share of women pursuing these treatments for weight management pay cash whether or not they carry good insurance